Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Formoterol hydrofluoroalkane inhalation - Chiesi

Drug Profile

Formoterol hydrofluoroalkane inhalation - Chiesi

Alternative Names: Atimos; CHF 1531; eformoterol; Eformoterol HFA inhalation - Chiesi; Forair; formoterol fumarate; Formoterol HFA inhalation - Chiesi; Formoterol HFA Modulite; Formoterol Modulite

Latest Information Update: 23 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Jul 2018 Chiesi Farmaceutici completes the phase II FLASH trial in Asthma in USA (Inhalation) (NCT03086460)
  • 05 Dec 2017 Phase II development is ongoing in USA for Asthma
  • 08 Sep 2017 Chiesi Farmaceutici initiates enrolment in the phase II FLASH trial in Asthma in USA (Inhalation) (NCT03086460)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top